Fosun Adgenvax Biopharmaceutical

Fosun Adgenvax (Chengdu) Biopharmaceutical is a specialized vaccine subsidiary of Fosun Pharma, focused on the research, development, and manufacturing of human vaccines. The company operates advanced technology platforms for bacterial and viral vaccines, including polysaccharide/conjugate and recombinant protein technologies. Its lead product is a 13-valent pneumococcal conjugate vaccine (PCV13) currently in Phase 3 clinical trials, alongside a quadrivalent influenza vaccine also in late-stage development. Fosun Adgenvax aims to address significant unmet needs in infectious diseases and is currently pursuing a spin-off and initial public offering on the Hong Kong Stock Exchange to further scale its operations and R&D capabilities.